News and Announcements
dZhON’s Application For Early Stage Commercialisation Grant
- Published September 20, 2013 11:13AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
dZhON recently announced our progress in applying for an Early Stage Commercialisation Grant from Commercialisation Australia and we have been informed that this may have been misleading and imply progress or endorsement by Commercialisation Australia or the individuals involved. We apologise for any inconvenience caused, the use of biographical information without approval, or any implication this release may have had.
Although dZhON has now advanced to stage two of the application there is no guarantee that dZhON will be successful in later stages of the application and would like to clarify that neither Jordan Green nor Commercialisation Australia are endorsing this company’s fundraising efforts and encourage anyone wanting further information to contact us directly.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
